This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Big Screen: Leading Health Care Funds That Keep Costs Down

Despite their current malaise, long-term investors shouldn't write off all health care funds -- just the expensive ones.

Screen Gems: High Returns, Low Fees
Financial Services Funds
Small-Cap Growth Funds
Mid-Cap Growth Funds
Large-Cap Growth Funds
Tech Funds

Health funds led the market last year with a 55.4% average gain, compared with a 9.1% loss for the S&P 500 , as investors fled the cooling tech sector. This year pharmaceutical, biotech, HMO and hospital stocks are falling from last year's high valuations, and health care funds are falling with them, trailing all stock fund categories with a 8.2% loss so far this year, according to Morningstar. In fact, only one health fund, the broker-sold (GGHCX), is in the black since Jan. 1.

If you're rattled, I don't blame you, but if we look beyond these funds' mercurial streak over the past 14 months or so, we see a more attractive picture. Given the wave of aging baby boomers, it's logical to suspect that demand for health care will grow in coming years. And health care stocks haven't exactly been wallflowers. Over the past 10 years, the average health fund's 18.6% annualized return tops the S&P 500 by more than two percentage points.

Bad Health
It's been a tough year so far for health care funds
Source: Morningstar. Annualized performance figures through Feb. 13.

So, this year's weakness might give you a good opportunity to add a health fund without paying last year's pie-in-the-sky valuations. As usual, the Big Screen is helping you winnow the field. We screened the 41-fund category to find those that beat their average peer over the past one- and three-year periods, while also having expenses below the category's rather steep 1.76% average because high fees can erode your investment over time. You wouldn't think these criteria are that stringent, but we're left with just three funds.

In other screens along this theme, we also yanked out funds that charged a load or sales charge, but only one no-load fund made the cut, the (VGHCX) fund.

Here are the three funds that cleared our hurdles, ranked by their annualized gains over the past three years.

Leading Health Care Funds
Fund 3-Year Annualized 1-Year Return Load/No-Load
(VGHCX) 28 44.6 No-Load
(MAHCX) 24.2 21.9 Load
(HCRAX) 23 26.7 Load
Avg. Health care fund 21.1 20.4 N/A
S&P 500 10.4 -3.8 N/A
Source: Morningstar. Annualized performance figures through Feb. 13.

When we screened health funds just a couple of months ago, the list was longer, with many biotech and biotech-heavy health funds because many of these cutting-edge drug shops saw their shares rocket to triple-digit gains in 1999 and last year. But they've since cooled, so today's list is mostly comprised of more diversified sector funds. That might sound like an oxymoron, but broader sector funds are best for most investors.

The best example of a diversified approach might be the no-load Vanguard Health Care fund, the nation's largest sector fund with more than $17 billion in assets. Ed Owens has run this fund since its 1984 inception, and he tends to spread its vast assets broadly, adjusting his industry weightings modestly and opportunistically.

That might sound like a vanilla approach, but Owens has beaten the S&P 500 and at least 70% of his peers over the past one-, three-, five- and 10-year periods, according to Morningstar. The fund also carries the category's lowest expense ratio, 0.39%, but to keep inflows manageable Vanguard has raised the fund's minimum investment for taxable and IRA accounts to a whopping $25,000.

If you're looking for another no-load option, the pickings are pretty slim. You might want to look at the (DGHCX) fund, but only if you're an aggressive investor who doesn't mind a strong biotech/pharmaceutical-stock flavor. The fund rode those sectors to a heady 73% gain last year, but its 10.7% gain over the past 12 months lags more than 80% of its peers, according to Morningstar.

You might be tempted to look at the no-load (FHLSX) fund, given the fund's solid reputation for growth investing, but there's reason to hold off on buying shares. After all, co-manager John Schroer just left, and the fund trails its average peer over the past one-, three-, five- and 10-year periods.

Otherwise, if you're looking for a health fund with a solid three-year record vs. its peers, you're probably looking at funds that levy loads.

You might look at (MAHCX), where Jordan Schreiber has held the reins since 1983. Schreiber, who stopped by TSC for a 10 Questions interview not too long ago, tends to own a broad swath of health stocks. He does rotate opportunistically among health care industries and that hasn't always gone well, but overall his track record is solid.

The fund, which carries a maximum 5.25% load or sales charge on Class A shares, beats its average peers and the S&P 500 over the past one-, three-, five- and 10-year periods.

The broker-sold (HCRAX) fund is probably worth a look, too. Manager Teresa McRoberts took the reins at the end of 1998, but she's been following the industry since 1985. The fund, which carries a maximum 5.25% front-end load or sales charge on Class A shares, has followed a diversified strategy to solid returns. The fund's one- and three-year returns beat the S&P 500 and its average peer.

Another fund that's worthy of consideration is the broker-sold (ETHSX) fund. Sam Isaly has run the fund since 1989, blending pharmaceutical and biotech picks with a healthy dose of foreign stocks.

The strategy has led to solid results. The fund beats more than 80% of its peers over the past one-, three-, five- and 10-year periods, according to Morningstar. The fund's 24.8% 10-year annualized gain, compared with 16.8% for the S&P 500, tops all health funds. Why isn't the fund on our list? Its 1.79% annual expense ratio is higher than the category's 1.76% average.

If you're curious about what stocks propelled the funds that are on our list, look no further. As usual, we tossed the funds on our list into a pot and sifted their cumulative top 10 holdings. Here you'll find names you know and expect, like pharmaceutical giant Pfizer (PFE), but there are also some names you might not know, like chart-topper AmeriSource Health (AAS), a pharmaceutical and health care wholesaler based in Malvern, Pa. The company's shares are up more than 240% over the past 12 months, according to Morningstar.

Under the Hood
The stocks with the biggest weighting in the combined portfolios
of the above funds
Stock Weighting in Top Three Funds Number of Top Three Funds Owning the Stock
HCA - The Healthcare Company(HCA - Get Report) 3.5 3
Pharmacia(PHA) 3 2
American Home Products(AHP - Get Report) 2.8 2
Eli Lilly(LLY) 2.4 3
Merck(MRK) 2.2 3
Baxter International(BAX) 2.1 3
Pfizer(PFE) 2.1 3
Bristol-Myers Squibb(BMY) 2 3
Tenet Healthcare(THC) 1.9 3
Stryker(SYK) 1.8 2
Source: Morningstar. Holdings as of funds' most recent portfolio reports.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AHP $11.19 0.00%
HCA $80.62 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs